Search

Your search keyword '"Magenta, Lorenzo"' showing total 42 results
Start Over Author "Magenta, Lorenzo"
42 results on '"Magenta, Lorenzo"'

1. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

Author

Aghemo, Alessio, Allice, Tiziano, Andreoni, Massimo, Angelico, Mario, Baldanti, Fausto, Barbaliscia, Silvia, Bertoli, Ada, Borghi, Vanni, Calvaruso, Vincenza, Cariti, Giuseppe, Craxì, Antonio, Francioso, Simona, Perno, Carlo Federico, Pozzoni, Pietro, Toniutto, Pier Luigi, Zazzi, Maurizio, Pérez, Ana Belén, Quilez, Cristina, Alados, Juan Carlos, Cabezas, Joaquin, Ruiz-Tapiador, Juan Ignacio Arenas, Jimenez, Miguel, Pascasio-Acevedo, Juan Manuel, Rodriguez, Manuel Alberto Macias, Zabal, Jose Miguel Rosales, Deltoro, Miguel García, Sapiña, Ana María Martinez, Fuentes, Ana, Chueca, Natalia, Berg, Christoph P., Herrmann, Andreas, Stallmach, Andreas, Port, Kerstin, Katja Deterding, M., Wedermeyer, Heiner, Cornberg, Markus, Manns, Michael P., Moreno, Christophe, Wiesch, Julian Schulze zur, Piecha, Felix, Lohse, Ansgar, Siebler, Jürgen, Kordecki, Nikolaus, Magenta, Lorenzo, Jäger, Burkhard, Möller, Hjördis, Heyne, Renate, Beyer, Tomas, Grunwald, Stephan, Baumgarten, Axels, Jägel-Guedes, Eva, Schmidt, Wolfgang, Dietz, Julia, Di Maio, Velia Chiara, de Salazar, Adolfo, Merino, Dolores, Vermehren, Johannes, Paolucci, Stefania, Kremer, Andreas E., Lara, Magdalena, Pardo, Maria Rodriguez, Zoller, Heinz, Degasperi, Elisabetta, Peiffer, Kai-Henrik, Sighinolfi, Laura, Téllez, Francisco, Graf, Christiana, Ghisetti, Valeria, Schreiber, Jonas, Fernández-Fuertes, Elisa, Boglione, Lucio, Muñoz-Medina, Leopoldo, Stauber, Rudolf, Gennari, William, Figueruela, Blanca, Santos, Jesús, Lampertico, Pietro, Zeuzem, Stefan, Ceccherini-Silberstein, Francesca, García, Federico, and Sarrazin, Christoph

Published
2021
Full Text
View/download PDF

2. Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)

Author

Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, Manuel, Oriol, Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, and Manuel, Oriol

Abstract

[Background] The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so new vaccination strategies are needed in this population., [Methods] Adult SOT recipients from 9 transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. Patients were randomized (1:1:1) to a MF59-adjuvanted or a high-dose vaccine (intervention), or a standard vaccine (control), with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least 1 vaccine strain at 28 days postvaccination. Secondary outcomes included polymerase chain reaction–confirmed influenza and vaccine reactogenicity., [Results] A total of 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n = 198; MF59-adjuvanted, n = 205; high-dose, n = 195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs standard vaccine, 0.20; 97.5% confidence interval [CI], .12–1); P < .001; difference in high-dose vs standard vaccine, 0.24 [95% CI, .16–1]; P < .001; difference in MF59-adjuvanted vs standard vaccine, 0.17 [97.5% CI, .08–1]; P < .001). Influenza occurred in 6% of the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild., [Conclusions] In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate.

Published
2024

3. Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial

Author

Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, et al, Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, and et al

Abstract

BACKGROUND The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so that new vaccination strategies are needed in this population. METHODS Adult SOT recipients from nine transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. High, with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least one vaccine strain at 28 days post-vaccination. Secondary outcomes included PCR-confirmed influenza and vaccine reactogenicity. RESULTS 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n=198; MF59-adjuvanted, n=205; high-dose, n=195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs. standard vaccine, 0.20 [97.5% CI 0.12-1]; p<0.001; difference in high-dose vs. standard vaccine, 0.24 [95% CI 0.16-1]; p<0.001; difference in MF59-adjuvanted vs. standard vaccine, 0.17 [97.5% CI 0.08-1]; p<0.001). Influenza occurred in 6% the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild. CONCLUSIONS In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate. TRIAL REGISTRATION Clinicaltrials.gov NCT03699839.

Published
2024

4. Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial).

Author

Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, and Steiger, Jürg

Subjects
INFLUENZA prevention, INFLUENZA vaccines, HEMAGGLUTINATION tests, CONFIDENCE intervals, VACCINE immunogenicity, PATIENTS, VACCINE effectiveness, RANDOMIZED controlled trials, COMPARATIVE studies, DESCRIPTIVE statistics, RESEARCH funding, POLYMERASE chain reaction, STATISTICAL sampling, TRANSPLANTATION of organs, tissues, etc., EVALUATION
Abstract

Background The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so new vaccination strategies are needed in this population. Methods Adult SOT recipients from 9 transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. Patients were randomized (1:1:1) to a MF59-adjuvanted or a high-dose vaccine (intervention), or a standard vaccine (control), with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least 1 vaccine strain at 28 days postvaccination. Secondary outcomes included polymerase chain reaction–confirmed influenza and vaccine reactogenicity. Results A total of 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n = 198; MF59-adjuvanted, n = 205; high-dose, n = 195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs standard vaccine, 0.20; 97.5% confidence interval [CI],.12–1); P <.001; difference in high-dose vs standard vaccine, 0.24 [95% CI,.16–1]; P <.001; difference in MF59-adjuvanted vs standard vaccine, 0.17 [97.5% CI,.08–1]; P <.001). Influenza occurred in 6% of the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild. Conclusions In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate. Clinical Trials Registration Clinicaltrials.gov NCT03699839. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Immunogenicity, Efficacy, and Safety of High-Dose Trivalent vs. MF59-Adjuvanted Trivalent vs. Standard-Dose Non-Adjuvanted Quadrivalent Influenza Vaccine in Solid Organ Transplant Recipients: A Randomised Clinical Trial.&nbsp;The STOP-FLU Trial

Author

Mombelli, Matteo, primary, Neofytos, Dionysios, additional, Huynh-Do, Uyen, additional, Sánchez-Céspedes, Javier, additional, Stampf, Susanne, additional, Golshayan, Dela, additional, Dahdal, Suzan, additional, Stirnimann, Guido, additional, Schnyder, Aurelia, additional, Garzoni, Christian, additional, Venzin, Reto M., additional, Magenta, Lorenzo, additional, Schönenberger, Melanie, additional, Walti, Laura N., additional, Hirzel, Cédric, additional, Munting, Aline, additional, Dickenmann, Michael, additional, Koller, Michael, additional, Aubert, John-David, additional, Steiger, Jurg, additional, Pascual, Manuel, additional, Müller, Thomas F., additional, Schuurmans, Macé M., additional, Berger, Christoph, additional, Binet, Isabelle, additional, Villard, Jean, additional, Mueller, Nicolas J., additional, Egli, Adrian, additional, Cordero, Elisa, additional, van Delden, Christian, additional, Manuel, Oriol Josep, additional, and Study, Swiss Transplant Cohort, additional

Published
2023
Full Text
View/download PDF

6. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index

Author

Bachofner, Jacqueline A., Valli, Piero V., Kröger, Arne, Bergamin, Irina, Künzler, Patrizia, Baserga, Adriana, Braun, Dominique, Seifert, Burkhardt, Moncsek, Anja, Fehr, Jan, Semela, David, Magenta, Lorenzo, Müllhaupt, Beat, Terziroli Beretta‐Piccoli, Benedetta, and Mertens, Joachim C.

Published
2017
Full Text
View/download PDF

7. Efficacy of Low-Dose Intermittent Subcutaneous Interleukin (IL)-2 in Antiviral Drug-Experienced Human Immunodeficiency Virus-Infected Persons with Detectable Virus Load: A Controlled Study of 3 IL-2 Regimens with Antiviral Drug Therapy

Author

Tambussi, Giuseppe, Ghezzi, Silvia, Nozza, Silvia, Vallanti, Giuliana, Magenta, Lorenzo, Guffanti, Monica, Brambilla, Andrea, Vicenzi, Elisa, Carrera, Paola, Racca, Sara, Soldini, Laura, Gianotti, Nicola, Murone, Michelangelo, Veglia, Fabrizio, Poli, Guido, and Lazzarin, Adriano

Published
2001

9. Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

Author

Yilmaz, Bahtiyar; https://orcid.org/0000-0003-1888-9226, Ruckstuhl, Lisa, Müllhaupt, Beat; https://orcid.org/0000-0002-9020-8192, Magenta, Lorenzo, Kuster, Melanie Harrer, Clerc, Olivier, Torgler, Ralph, Semmo, Nasser, Yilmaz, Bahtiyar; https://orcid.org/0000-0003-1888-9226, Ruckstuhl, Lisa, Müllhaupt, Beat; https://orcid.org/0000-0002-9020-8192, Magenta, Lorenzo, Kuster, Melanie Harrer, Clerc, Olivier, Torgler, Ralph, and Semmo, Nasser

Abstract

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fresh stool sample the week before their study visit, from which microbial DNA was extracted and sequenced for the 16S rRNA region in an Illumina MiSeq2 platform. Microbial and statistical analyses were conducted to determine the alpha-diversity (number of different taxa within a sample) and beta-diversity (number of overlapping taxa between samples). Stool samples from 58 patients were eligible for analysis. There were 27 patients with HCV genotype 1, 10 with genotype 2, 16 with genotype 3, and 5 with genotype 4. No statistically significant differences in gut microbiota diversity, species richness, or microbial community pattern were found at baseline and at post-treatment Week 12. Lack of statistically significant differences remained consistent in further analysis by demographic and baseline disease characteristics. Surprisingly, no statistically significant changes in alpha- and beta-diversity were seen in the microbiota after GLE/PIB treatment, though there was a trend toward less richness over time. Further investigation is needed into this unexpected outcome to better understand the role of HCV treatment and the gut microbiota.

Published
2021

10. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland

Author

Müllhaupt, Beat, Semela, David, Ruckstuhl, Lisa, Magenta, Lorenzo, Clerc, Olivier, Torgler, Ralph, Negro, Francesco, Semmo, Nasser, Müllhaupt, Beat, Semela, David, Ruckstuhl, Lisa, Magenta, Lorenzo, Clerc, Olivier, Torgler, Ralph, Negro, Francesco, and Semmo, Nasser

Abstract

AIM OF THE STUDY In the era of pangenotypic treatment regimens against hepatitis C virus (HCV) infection, data from postmarketing observational studies are crucial to better understand the treatment patterns used in specific countries and treatment outcomes under real-life conditions. We report data from Switzerland from an ongoing, multinational postmarketing observational study on the pangenotypic treatment regimen of glecaprevir (GLE; NS3/4A protease inhibitor) and pibrentasvir (PIB; NS5A inhibitor), coformulated as GLE/PIB. METHODS Adults infected with chronic HCV genotypes 1–6 were eligible to participate in the postmarketing observational study if they started GLE/PIB at the treating physician’s discretion. The primary objective was to evaluate the effectiveness of GLE/PIB based on sustained virological response 12 weeks after completion of treatment (SVR12); secondary outcomes included patient-reported outcomes (Fatigue Severity Scale, Work Productivity and Activity Impairment Questionnaire, Pictorial Representation of Illness and Self Measure tool) and safety data. RESULTS In Switzerland, 109 patients were enrolled, and 107 patients received ≥1 dose GLE/PIB (94.4% non-cirrhotic; 43.9%/14.0%/29.0%/13.1% GT1/GT2/GT3/GT4; 89.7% treatment-naïve; 91.6% assigned to an 8-week GLE/PIB regimen). Overall, 95 of 98 patients with sufficient follow-up data (96.9%) achieved SVR12 (95% confidence interval [CI] 91.4% to 99.0%), and 91.6% in the safety population (including six non-virological failures). The three treatment failures were due to relapse. All three failures were GT3, without cirrhosis and treatment naïve. Patient-reported outcomes improved as well. GLE/PIB was well tolerated with no serious adverse events and no adverse events leading to discontinuation or interruption of GLE/PIB treatment. CONCLUSION These real-world effectiveness and safety data of GLE/PIB in patients from Switzerland were consistent with those seen in the multinatio

Published
2021

11. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

Author

Dietz, Julia, primary, Di Maio, Velia Chiara, additional, de Salazar, Adolfo, additional, Merino, Dolores, additional, Vermehren, Johannes, additional, Paolucci, Stefania, additional, Kremer, Andreas E., additional, Lara, Magdalena, additional, Pardo, Maria Rodriguez, additional, Zoller, Heinz, additional, Degasperi, Elisabetta, additional, Peiffer, Kai-Henrik, additional, Sighinolfi, Laura, additional, Téllez, Francisco, additional, Graf, Christiana, additional, Ghisetti, Valeria, additional, Schreiber, Jonas, additional, Fernández-Fuertes, Elisa, additional, Boglione, Lucio, additional, Muñoz-Medina, Leopoldo, additional, Stauber, Rudolf, additional, Gennari, William, additional, Figueruela, Blanca, additional, Santos, Jesús, additional, Lampertico, Pietro, additional, Zeuzem, Stefan, additional, Ceccherini-Silberstein, Francesca, additional, García, Federico, additional, Sarrazin, Christoph, additional, Aghemo, Alessio, additional, Allice, Tiziano, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Baldanti, Fausto, additional, Barbaliscia, Silvia, additional, Bertoli, Ada, additional, Borghi, Vanni, additional, Calvaruso, Vincenza, additional, Cariti, Giuseppe, additional, Craxì, Antonio, additional, Francioso, Simona, additional, Perno, Carlo Federico, additional, Pozzoni, Pietro, additional, Toniutto, Pier Luigi, additional, Zazzi, Maurizio, additional, Pérez, Ana Belén, additional, Quilez, Cristina, additional, Alados, Juan Carlos, additional, Cabezas, Joaquin, additional, Ruiz-Tapiador, Juan Ignacio Arenas, additional, Jimenez, Miguel, additional, Pascasio-Acevedo, Juan Manuel, additional, Rodriguez, Manuel Alberto Macias, additional, Zabal, Jose Miguel Rosales, additional, Deltoro, Miguel García, additional, Sapiña, Ana María Martinez, additional, Fuentes, Ana, additional, Chueca, Natalia, additional, Berg, Christoph P., additional, Herrmann, Andreas, additional, Stallmach, Andreas, additional, Port, Kerstin, additional, Katja Deterding, M., additional, Wedermeyer, Heiner, additional, Cornberg, Markus, additional, Manns, Michael P., additional, Moreno, Christophe, additional, Wiesch, Julian Schulze zur, additional, Piecha, Felix, additional, Lohse, Ansgar, additional, Siebler, Jürgen, additional, Kordecki, Nikolaus, additional, Magenta, Lorenzo, additional, Jäger, Burkhard, additional, Möller, Hjördis, additional, Heyne, Renate, additional, Beyer, Tomas, additional, Grunwald, Stephan, additional, Baumgarten, Axels, additional, Jägel-Guedes, Eva, additional, and Schmidt, Wolfgang, additional

Published
2021
Full Text
View/download PDF

12. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy

Author

Zuber, Jean-Philippe, Calmy, Alexandra, Evison, John M., Hasse, Barbara, Schiffer, Veronique, Wagels, Thomas, Nuesch, Reto, Magenta, Lorenzo, Ledergerber, Bruno, Jenni, Rolf, Speich, Rudolf, and Opravil, Milos

Subjects
Cookery for hypertensives -- Care and treatment, Cookery for hypertensives -- Research, Hypertension -- Care and treatment, Hypertension -- Research, Highly active antiretroviral therapy -- Health aspects, HIV infection -- Care and treatment, HIV infection -- Research, Antiviral agents -- Health aspects, Antiviral agents -- Research, Health, Health care industry
Published
2004

16. Treatment cascade of hepatitis C in a non-university hospital setting, that uses a hub-and-spoke model, in southern Switzerland

Author

Baserga, Adriana, primary, Terziroli, Benedetta, additional, Magenta, Lorenzo, additional, Robatto, Antonella, additional, Balmelli, Manuela, additional, Moriggia, Alberto, additional, Hagara, Daniel, additional, Stadler, Odile, additional, Appadoo, Sheila, additional, De Gottardi, Andrea, additional, and Cerny, Andreas, additional

Published
2020
Full Text
View/download PDF

19. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study

Author

Semmo, Nasser, Müllhaupt, Beat, Ruckstuhl, Lisa; https://orcid.org/0000-0002-6934-0471, Magenta, Lorenzo, Clerc, Olivier, Torgler, Ralph, Semela, David, Semmo, Nasser, Müllhaupt, Beat, Ruckstuhl, Lisa; https://orcid.org/0000-0002-6934-0471, Magenta, Lorenzo, Clerc, Olivier, Torgler, Ralph, and Semela, David

Abstract

AIM Fatigue is the most commonly reported symptom of Hepatitis C Virus (HCV) infected patients and severely impacts their quality of life. The aim of this study was to measure the impact of 3D regimen treatment on the fatigue, daytime physical activity and sleep efficiency of HCV infected patients with fatigue. METHODS HEMATITE was an observational, prospective, open-label, single-arm, Swiss multi-centric study in mono-infected HCV genotype 1 patients. The 28 week observation period comprised of 4 weeks preparation, 12 weeks treatment and 12 weeks follow-up. Fatigue was assessed using the fatigue severity scale (FSS) questionnaire. Patients with FSS ≥ 4 (clinically significant fatigue) were included. The activity tracker, ActiGraph GT9X Link®, was used to measure daytime physical activity and sleep efficiency. Outcome analysis was performed on a scaled down intention to treat (sdITT) population, which excluded patients with insufficient tracker data at all study visits and a modified ITT (mITT) population, which consisted of patients with complete tracker data at all study visits. RESULTS Forty of 41 patients in the ITT population had a sustained virologic response 12 weeks post-treatment (SVR12). Mean baseline FSS score was 6.0 for the sdITT population and 5.9 for the mITT population and decreased from baseline to 12 weeks post-treatment by 2.6 (95% confidence interval [CI]: 2.1, 3.1) for the sdITT (n = 37) population and 2.8 (95% CI: 2.2, 3.4) for the mITT (n = 24) population. Mean daytime physical activity or sleep efficiency did not change considerably over the course of the study. CONCLUSION Measurement by the activity tracker of mean day time physical activity did not show a considerable change from baseline to SVR12 upon treatment with 3D regimen. Nevertheless, a reduction of fatigue as assessed with the validated fatigue severity scale (FSS) was observed, suggesting a causative role of HCV in this extrahepatic manifestation. TRIAL REGISTRATION ClinicalTrials

Published
2020

22. SAT-197-Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen)

Author

Semmo, Nasser, primary, Müllhaupt, Beat, additional, Ruckstuhl, Lisa, additional, Magenta, Lorenzo, additional, Clerc, Olivier, additional, Torgler, Ralph, additional, and Semela, David, additional

Published
2019
Full Text
View/download PDF

24. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis

Author

De Gottardi, Andrea, Trebicka, Jonel, Klinger, Christoph, Plessier, Aurélie, Seijo, Susana, Terziroli, Benedetta, Magenta, Lorenzo, Semela, David, Buscarini, Elisabetta, Langlet, Philippe, Görtzen, Jan, Puente, Angela, Müllhaupt, Beat, Navascuès, Carmen, Nery, Filipe, Deltenre, Pierre, Turon, Fanny, Engelmann, Cornelius, Arya, Rupen, Caca, Karel, Peck‐Radosavljevic, Markus, Leebeek, Frank W. G., Valla, Dominique, Garcia‐Pagan, Juan Carlos, Grønbæk, Henning, Beer, Jürg‐Hans, Genescà, Joan, Hidalgo, Canete, Vila, Carmen, Mihailovic, Jelena, Piscaglia, Fabio, Lasser, Luc, Fernandez‐Bermejo, Miguel, Procopet, Bogdan, Schouten, Jeoffrey, Spahr, Laurent, Sanchez, José Louis, Zipprich, Alexander, Sekhar, Mallika, Hernandez‐Guerra, Manuel, Laguna, La, Nevens, Frederik, Ferreira, Carlos Noronha, Heneghan, Michael, Albillos, Agustin, Llop, Elba, Dell'Era, Alessandra, La Mura, Vincenzo, Primignani, Massimo, Senzolo, Marco, Escarda, Ana, Mallorca, Palma, Riggio, Oliviero, Murad, Sarwa Darwish, Haas, Stephan, Bureau, Christophe, Berenguer, Marina, De Gottardi, Andrea, Trebicka, Jonel, Klinger, Christoph, Plessier, Aurélie, Seijo, Susana, Terziroli, Benedetta, Magenta, Lorenzo, Semela, David, Buscarini, Elisabetta, Langlet, Philippe, Görtzen, Jan, Puente, Angela, Müllhaupt, Beat, Navascuès, Carmen, Nery, Filipe, Deltenre, Pierre, Turon, Fanny, Engelmann, Corneliu, Arya, Rupen, Caca, Karel, Peck-Radosavljevic, Marku, Leebeek, Frank W. G., Valla, Dominique, Garcia-Pagan, Juan Carlo, on behalf of the VALDIG Investigators: [.., Fabio Piscaglia, ], University of Zurich, and Hematology

Subjects
Budd-Chiari syndrome, medicine.medical_specialty, Deep vein, 610 Medicine & health, 03 medical and health sciences, Anticoagulation, 0302 clinical medicine, Journal Article, medicine, Portal vein thrombosi, Cirrhosis, Portal vein thrombosis, Hepatology, Rivaroxaban, Cirrhosi, business.industry, medicine.disease, Thrombosis, 3. Good health, Surgery, Venous thrombosis, medicine.anatomical_structure, 10219 Clinic for Gastroenterology and Hepatology, Splanchnic vein thrombosis, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Apixaban, 2721 Hepatology, Liver function, business, medicine.drug
Abstract

BACKGROUND: Direct-acting oral anticoagulants (DOACs) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOACs and to report adverse effects, complications and short-term outcome.METHODS: Data collection including demographic information, laboratory values, treatment and complications through the Vascular Liver Disease Interest Group Consortium.RESULTS: Forty-five centres (90%) of the consortium completed the initial eCRF. We report here a series of 94 patients from 17 centres. Thirty-six patients (38%) had cirrhosis. Child-Pugh score was 6 (range 5-8), and MELD score 10.2 (range 6-19). Indications for anticoagulation were splanchnic vein thrombosis (75%), deep vein thrombosis (5%), atrial fibrillation (14%) and others (6%). DOACs used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26.5 months (non-cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding. Treatment with DOACs was stopped in three cases. The major reasons for choosing DOACs were no need for monitoring or inadequacy of INR to guide anticoagulation in cirrhotic patients. Renal and liver function did not change during treatment.CONCLUSIONS: A consistent number of patients with SVT and/or cirrhosis are currently treated with DOACs, which seem to be effective and safe. These data provide a basis for performing randomized clinical trials of DOACs vs. low molecular weight heparin or vitamin K antagonists.

Published
2017
Full Text
View/download PDF

25. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Author

Bachofner, Jacqueline, Valli, Piero V, Bergamin, Irina, Kröger, Arne, Künzler, Patrizia, Baserga, Adriana, Braun, Dominique L, Seifert, Burkhardt, Moncsek, Anja, Fehr, Jan, Semela, David, Magenta, Lorenzo, Müllhaupt, Beat, Terziroli Beretta-Piccoli, Benedetta, Mertens, Joachim, Swiss Hepatitis C Cohort Study, and University of Zurich

Subjects
10234 Clinic for Infectious Diseases, 10219 Clinic for Gastroenterology and Hepatology, virus diseases, 610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 2700 General Medicine, digestive system diseases
Published
2018

27. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Author

Bachofner, Jacqueline A, Valli, Piero V, Bergamin, Irina, Kröger, Arne, Künzler, Patrizia, Baserga, Adriana, Braun, Dominique L, Seifert, Burkhardt, Moncsek, Anja, Fehr, Jan, Semela, David, Magenta, Lorenzo, Müllhaupt, Beat, Terziroli Beretta-Piccoli, Benedetta, Mertens, Joachim, Swiss Hepatitis C Cohort Study, Bachofner, Jacqueline A, Valli, Piero V, Bergamin, Irina, Kröger, Arne, Künzler, Patrizia, Baserga, Adriana, Braun, Dominique L, Seifert, Burkhardt, Moncsek, Anja, Fehr, Jan, Semela, David, Magenta, Lorenzo, Müllhaupt, Beat, Terziroli Beretta-Piccoli, Benedetta, Mertens, Joachim, and Swiss Hepatitis C Cohort Study

Abstract

BACKGROUND The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete. AIMS OF THE STUDY We retrospectively and prospectively evaluated treatment results after the introduction of DAA in Switzerland in a cohort of patients with CHC. METHODS We examined 565 patients who received DAA treatment for CHC between November 2013 and June 2016 with regard to HCV genotype, fibrosis stadium, treatment and outcome. In addition, outcome of re-treatment and resistance-associated substitutions (RAS) in patients that did not achieve sustained virological response (SVR) were evaluated. The majority of patients participate in the Swiss Hepatitis C Cohort Study. Data were evaluated in an intention-to-treat and a modified intention-to-treat analysis. RESULTS Overall SVR rate for all patients was 94% (530 of 565, 95% CI 92-96%). Of 350 patients with HCV genotype 1 CHC, 335 achieved SVR, resulting in an SVR rate of 96% (335 of 350, 95% CI 94-98%). Patients with HCV genotype 2 achieved SVR in 94% (48 of 51, 95% CI 87-100%). Patients with HCV genotype 3 showed SVR of 92% (98 of 107, 95% CI 87-97%). In patients with HCV genotype 4, the SVR rate was substantially lower at 85% (49 of 57, 95% CI 76-94%). The rate of advanced liver fibrosis (Metavir F3/F4) assessed by means of liver biopsy or Fibroscan® in the entire patient population was 71% (404 of 565). Out of 35 patients that did not achieve SVR after DAA treatment, 32 had a relapse and 3 patients showed viral breakthrough. In 17 of 35 cases (49%) patients were treatment naïve and 21 of 35 patients (60%) were cirrhotic. RAS genotyping of HCV was performed in 14 patients. Nine of these 14 patients (60%) carried mutations in the NS5A region of the virus genome. Twenty-seven percent of patients who experienced treatment failure were not treated with recommended regimens as

Published
2018

28. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI

Author

Bachofner, Jacqueline A, Valli, Piero V, Kröger, Arne, Bergamin, Irina, Künzler, Patrizia, Baserga, Adriana, Braun, Dominique, Seifert, Burkhardt, Moncsek, Anja, Fehr, Jan, Semela, David, Magenta, Lorenzo, Müllhaupt, Beat, Terziroli Beretta-Piccoli, Benedetta, Mertens, Joachim C, University of Zurich, and Mertens, Joachim C

Subjects
10234 Clinic for Infectious Diseases, 10219 Clinic for Gastroenterology and Hepatology, 610 Medicine & health, 2721 Hepatology, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI)
Published
2017

30. Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy

Author

Zuber, Jean-Philippe, Calmy, Alexandra, Evison, John M., Hasse, Barbara, Schiffer, Veronique, Wagels, Thomas, Nuesch, Reto, Magenta, Lorenzo, Ledergerber, Bruno, Jenni, Rolf, Speich, Rudolf, Opravil, Milos, Zuber, Jean-Philippe, Calmy, Alexandra, Evison, John M., Hasse, Barbara, Schiffer, Veronique, Wagels, Thomas, Nuesch, Reto, Magenta, Lorenzo, Ledergerber, Bruno, Jenni, Rolf, Speich, Rudolf, and Opravil, Milos

Abstract

This study aimed to assess the long-term course of pulmonary arterial hypertension related to infection with human immunodeficiency virus (PAHRH) and the influence of antiretroviral therapy (ART) on its characteristics. We retrospectively analyzed all 47 patients in the Swiss HIV Cohort Study in whom PAHRH was diagnosed. Among 35 patients who underwent follow-up Doppler echocardiography, the right ventricular systolic pressure over right atrial pressure gradient increased by a median of 25 mm Hg in 9 patients who had not received ART, decreased by a median of 3 mm Hg in 12 patients who had received nucleoside analogs, and decreased by a median of 21 mm Hg in 14 patients who had received highly active ART (HAART) (P < .005). Among all 47 patients, median duration of survival after PAHRH diagnosis was 2.7 years. HAART significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect of combination ART in patients with PAHRH

Published
2017

31. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index

Author

Bachofner, Jacqueline A., primary, Valli, Piero V., additional, Kröger, Arne, additional, Bergamin, Irina, additional, Künzler, Patrizia, additional, Baserga, Adriana, additional, Braun, Dominique, additional, Seifert, Burkhardt, additional, Moncsek, Anja, additional, Fehr, Jan, additional, Semela, David, additional, Magenta, Lorenzo, additional, Müllhaupt, Beat, additional, Terziroli Beretta-Piccoli, Benedetta, additional, and Mertens, Joachim C., additional

Published
2016
Full Text
View/download PDF

33. 1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies

Author

Feld, Jordan J., primary, Weiland, Ola, additional, Marinho, Rui Tato, additional, Wedemeyer, Heiner, additional, Jacobson, Ira M., additional, Jensen, Donald M., additional, Hassanein, Tarek, additional, De Ledinghen, Victor, additional, Diago, Moisés, additional, Magenta, Lorenzo, additional, De Knegt, Robert J., additional, Xiong, Junyuan J., additional, Coakley, Eoin, additional, Baykal, Tolga, additional, Tatsch, Fernando, additional, and Foster, Graham R., additional

Published
2014
Full Text
View/download PDF

34. Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy

Author

Bucher, Heiner C., primary, Richter, Werner, additional, Glass, Tracy R., additional, Magenta, Lorenzo, additional, Wang, Qing, additional, Cavassini, Matthias, additional, Vernazza, Pietro, additional, Hirschel, Bernard, additional, Weber, Rainer, additional, Furrer, Hansjakob, additional, Battegay, Manuel, additional, and Bernasconi, Enos, additional

Published
2012
Full Text
View/download PDF

35. Efficacy of Low-Dose Intermittent Subcutaneous Interleukin (IL)-2 in Antiviral Drug--Experienced Virus Load: A Controlled Study of 3 IL-2 Regimens with Antiviral Drug Therapy.

Author

Tambussi, Giuseppe, Nozza, Silvia, Magenta, Lorenzo, Guffanti, Monica, Gianotti, Nicola, Lazzarin, Adriano, Ghezzi, Silvia, Vallanti, Giuliana, Brambilla, Andrea, Vicenzi, Elisa, Poli, Guido, Carrera, Paola, Racca, Sara, Soldini, Laura, Murone, Michelangelo, and Veglia, Fabrizio

Subjects
INTERLEUKIN-2, HIV-positive persons, HIV infections, THERAPEUTICS
Abstract

Evaluates the safety and efficacy of three regimens of intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced HIV-infected persons with detectable virus load. Impact of IL-2 regimens on circulating CD4 T cells; Plasma viremia; Drug resistance genotyping; Therapy changes and toxicity.

Published
2001
Full Text
View/download PDF

36. Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial.

Author

Barda, Beatrice, Di Mari, Bruno, Soldini, Emiliano, Di Bartolomeo, Claudia, Bissig, Maurizia, Baserga, Adriana, Robatto, Antonella, Magenta, Lorenzo, Forlenza, Rossella, and Cerny, Andreas

Subjects
*METHYLENE blue, *COVID-19 pandemic, *SARS-CoV-2, *PATIENT safety, *COVID-19
Abstract

The SARS-CoV-2 pandemic has revolutionized the scientific and medical world in recent years. Methylene blue (MB) is a well-known molecule. The aim of our study was to assess the efficacy of MB against early-phase SARS-CoV-2 infections. All patients with a positive swab for SARS-CoV-2 were eligible for the trial. The intervention was a starting dose of 200 mg MB or placebo in the morning and 100 mg in the evening on the first day and afterwards the standard daily dose of 200 mg. Patients were followed up for safety and efficacy until day 84. We analyzed 21 patients for the safety profile and 19 for the efficacy objective: of these, there were 11 in the MB group and 8 in the placebo one. In both groups, patients had undetectable RNA from day 3 and 10 out of 11 subjects in the MB group were virus free by day 12 vs. 6 out of 8 in the placebo one. None of the patients experienced serious adverse events. MB has proved to be a safe and well-tolerated drug. We did not find superiority of efficacy or viral clearance of MB compared to the placebo. Given the good in vitro efficacy, larger studies are needed to assess MB efficacy against COVID-19 in vivo. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin-2

Author

Fox, Zoe, Antunes, Francisco, Davey, Rick, Gazzard, Brian, Klimas, Nancy, Labriola, Ann, Losso, Marcelo, Neaton, James D., Phillips, Andrew N., Ruxrungtham, Kiat, Staszewski, Schlomo, Weiss, Laurence, Lundgren, Jens D., Abrams, Donald I., Cooper, David A., Darbyshire, Janet H., Duncan, William R., Emery, Sean, Lane, H. Clifford, Lehrman, Sandra, Aguilar, Liliana, Betina Angel, Eleonora, Aquilia, Silvia, Belloso, Waldo, Benetucci, Jorge, Bittar, Victor, Cahn, Pedro, Casiro, Arnaldo, Contarelli, Jorge, Corral, Jorge, Daciuk, Lucia, David, Daniel, Ferrari, Ines, Fridman, Diego, Galache, Viviana, Guaragna, Graciela, Ivalo, Silvina, Laplume, Hector, Lanusse, Isabel, Lasala, Maria B., Lattes, Roberta, Lasovsky, Jaime, Lopardo, Gustavo, Lourtau, Leonardo, Lupo, Sergio, Maranzana, Aldo, Marson, Cristina, Massera, Lucila, Del Lujan Sanchez, Marisa, Somenzini, Carla, Tocci, Mariel, Algar, Sally, Anderson, Jonathan, Baker, David, Blavius, Kathy, Bloch, Mark, Boyle, Michael, Bradford, David, Britton, Phillip, Carrall, Leah, Carr, Andrew, Chuah, John, Curry, Michael, D Arcy-Evans, Clive, Dobson, Pauline, Doong, Nicholas, Egan, Cari, Ferguson, Wendy, Finlayson, Robert, French, Martyn, Frater, Anthony, Gold, Julian, Habel, Philip, Haig, Kay, Holland, Rohan, Hyland, Natalie, Hoy, Jennifer, Hudson, Jeff, James, Robyn, Leung, Jenny, Lowe, Kaye, Macrae, Karen, Mcmurchie, Marilyn, Medland, Nicholas, Miller, Samantha, Murray, Jo, Newman, Rosie, Orth, David, Patching, Julie, Primrose, Ruth, Ree, Hugo, Richardson, Robyn, Rogers, Gary, Roney, Janine, Roth, Norman, Sarangapany, Jeganathan, Shaw, David, Silberberg, Carol, Skett, Jenny, Williams, Leah, Soo, Tuck Meng, Sowden, David, Street, Alan, Vale, Robyn, Villella, Claudio, Walker, Alan, Watson, Ashley, Wendt, Ngaire, Wood, Helen, Youds, David, Aichelburg, Alexander, Rieger, Armin, Vetter, Norbert, Clumeck, Nathan, Wit, Stephane, Kabeya, Kabamba, O Doherty, Elizabeth, Amorim, Cristiane Sales, Basso, Caritas Relva, Lewi, David Salamao, Pereira, Luiz Carlos, Da Silva, Mariliza, Lobato Souza, Tamara Newman, Angel, Jonathan, Bouchard, Pierrette-Rolande, Clark, Fran, Cohen, Jeff, Dambreville, Mimose, Ellis, Michele, Fiset, Stephan, Foster, Andrea, Fraser, Christopher, Gagnon, Susan, Gilmour, Janet, Guenette, Richard, Haldane, Heather, Hawley-Foss, Nanci, Hyndman, Susan, Johnston, Lynn, Jubinville, Nathalie, Juneau, Francoise, Kelleher, Lynn, Lapointe, Lyne, Latendre-Paquette, Judy, Lindemulder, Adeline, Mashinter, Laura, Lefebvre, Eric, Mcfarland, Nancy, Morisseau, Chantal, O Neill, Robert, Piche, Alain, Ralph, Edward, Rouleau, Danielle, Routy, Jean-Pierre, Sandre, Roger, Schmidt, Shelley, Shafran, Stephen, Smaill, Fiona, Stromberg, Dale, Trepanier, Jean-Marc, Trottier, Sylvie, Veal, Susanne, Walmsley, Sharon, Weiss, Karl, Williams, Kurt, Young, Mavis, Zaleschuk, Barbara, Zarowny, Don, Baadegaard, Bente, Black, Finn, Boedker, Kirsten, Gerstoft, Jan, Jensen, Lene, Mathiesen, Lars, Nielsen, Henrik, Pedersen, Court, Petersen, Dorthe, Aboulker, Jean-Pierre, Baakili, Adyb, Bengrait, Nafissa, Bensalem, Maryse, Berthe, Huguette, Bloche, Martin, Bazin, Claude, Boue, Francois, Bouvet, Elisabeth, Brancon, Christiane, Capitant, Catherine, Ceppi, Carole, Cheneau, Christine, Coutellier, Anne, Chennebault, Jean Marie, Coquet, Fabienne, Truchis, Pierre, Delavalle, Anne-Marie, Frixon-Marin, Veronique, Gastaut, Jean-Albert, Delfraissy, Francois, Eliaszeicz, Muriel, Gallais, Herve, Gataut, Jean-Albert, Gilquin, Jacques, Gonzalez-Canali, Gustavo, Gaudebout, Chrisiane, Goujard, Cecile, Hoen, Bruno, Honore, Patricia, Jarousse, Bernard, Lang, Jean-Marie, Lefebvre, Benedict, Levy, Yves, Loison, Jocelyne, Maignan, Aline, Meynard, Jean-Luc, Michon, Christophe, Mole, Martin, Marsal, Laurence, Matheron, Sophie, Mortier, Emmanuel, Oksenhendler, Eric, Poirier, Sandrine, Picard-Dahan, Catherine, Ravaux, Isabelle, Raffi, Francois, Raguin, Gilles, Reynes, Jacque, Rozenbaum, Willy, Salmon, Dominique, Simon, Anne, Spiridon, Gabriella, Viard, Jean-Paul, Vidal, Michele, Zucman, David, Bergmann, Frank, Brockmeyer, Norbert, Faetkenheuer, Gerd, Fenske, Stefan, Gey, Daniela, Goebel, Frank-Detlef, Goetsch, Martina, Hartmann, Martin, Klinker, Hartwig, Kremer, Gisela, Mantzsch, Kathleen, Mauss, Stefan, Rockstroh, Juergen, Rotty, Jessica, Rund, Ellen, Schneider, Katrin, Schuermann, Dirk, Staszweski, Schlomo, Tilmann, Klaus, Vogel, Martin, Bentwich, Zvi, Drora, Goldstain, Kedem, Eynat, Lang, Ruth, Levi, Itzic, Maayan, Shlomo, Magen, Eli, Mamorsky, Merav, Pilpul, Anat, Pollack, Shimon, Sthoeger, Zev, Vered, Hadas, Yust, Israel, Lyons, Fiona, Mulcahy, Fiona, Rochford, Annette, Auiti, Fernando, Angarano, Gioacchino, Bertelli, Davide, Bini, Teresa, Bruno, Raffaele, Cadeo, Gian Pietro, Carosi, Giampietro, D Arminio Monforte, Antonella, Del Giacco, Sergio, Di Pietro, Massimo, Esposito, Roberto, Filice, Gaetano, Gavazzeni, Gabriella, Guaraldi, Giovanni, Indiveri, Francesco, Lazzarin, Adriano, Mazzotta, Francesco, Minolli, Lorenzo, Montroni, Maria, Moroni, Mauro, Nozza, Silvia, Pastor, Guiseppe, Poli, Guido, Raise, Enzo, Romagnani, Sergio, Rusconi, Vega, Sacchi, Paolo, Suter, Fredy, Tambussi, Giuseppe, Tirelli, Umberto, Fraser, Helen, Iwamoto, Aikichi, Kikuchi, Yoshida, Mori, Masahiko, Nakamura, Tetsuya, Odawara, Takashi, Oka, Shinichi, Shirasaka, Takuma, Takano, Misao, To, Junichiro, Ueta, Chisato, El Filali, Kamal, Erradey, Ikbale, Himmich, Hakima, Blok, W., Borleffs, J., Bravenboer, B., Bronveld, W., Claessen, F., Duurvoort, Maurice, Ferwerda, J., Frissen, P., Hulshoff, Nicolette, Juttman, Job, Kauffmann, R., Koopmans, P., Kroon, F., Lowe, Selwyn, Leemhuis, M., Meenhorst, P., Boer, Lieselotte Posthuma, Reiss, Peter, Reinders-Folmer, S., Richter, C., Santegoets, Rick, Schoemaker, Marijke, Schrey, G., Sprenger, Herman, Ten Veen, Jacob, Tessalaar, Judith, Ende, M., Vall, H., Eeden, Arne, Leeuwen, Remko, Vermeulen, Joost, Ten Kate, Reinier W., Boxtel, Renee, Eden, Arne, Ven, Bernadette, Meulen, Piet, Ten Napei, C., Vriesendrop, R., Bruun, Johann, Bakowska, Elzbieta, Beniowski, Marek, Boron-Kaczmarska, Anna, Gasiorowski, Jacek, Gxadysz, Andrzej, Horban, Andrzej, Knysz, Brygida, Mularska, Elzbieta, Pynka, Magdelena, Szymczak, Aleksandra, Aldir, Isabel, Doroana, Manuela, Duque, Luis, Mansinho, Kamal, Pinto, Inez, Valadas, Emilia, Vera, Jose, Foo, Estelle, Panchalingham, Anushia, Lim, Poh Lian, Paton, Nick, Peperstraete, Bernard, Quek, Angela, Alcazar-Caballero, Rosario, Arrizabalaga, Julio, Bouza, Emilio, Cepeda, Concepcion, Barron, Xabier, Cervero Jimenez, Miguel, Clotet, Bonaventura, Cortes, Luis, Domingo, Pere, Fernandez, Pompeyo, Fernandez-Cruz, Eduardo, Fuster, Montserrat, Gatell, Jose, Gijon, Paloma, Gil, Ignacio, Gonzales-Lahoz, Juan, Gonzalez, Alicia, Hernandez, Manuel, Iribarren, Jose, Jimenez, Miguel, Knobel, Hernando, Leon, Agathe, Carlos Lopez, Juan, Lozano, Angeles, Lopez, Paco, Moreno, Jose, Munoz, Rosa, Padilla, Belen, Parras, Angeles, Pastor, Antoni, Pedreira, Jose, Pristo, Julio, Pena, Jose, Roca, Victor, Rubio, Rafael, Sanchez Rivera, Jose, Sanz, Jesus, Tamargo, Lara, Torres, Rafael, Pehrson, Pehr O., Sandstrom, Eric, Bernasconi, Enos, Gurtner, Vanina, Magenta, Lorenzo, Ampunpong, Uangarun, Bowonwatnuwong, Chureeratana, Chanchai, Patimoaporn, Chetchotisakd, Ploenchan, Chuenyam, Thesinee, Duncombe, Chris, Horsakulthai, Mannassinee, Kantipong, Pacharee, Liddy, John, Phanuphak, Praphan, Pongsurachet, Vithaya, Seekaew, Samroeng, Sonjai, Areerat, Subsri, Nuramon, Suwanagool, Surapol, Techasathit, Wichai, Wankoon, Jaturaporn, Adebiyi, Aderonke, Aldam, Diana, Alexander, Ian, Angus, Brian, Barber, Tristan, Bonnington, Sue, Care, Chris, Carroll, Anne, Cornforth, David, Donaldson, Oscar, Druiff, Laurance, Easterbrook, Philippa, Edwards, Beverley, Ellis, Chris, Fisher, Martin, Fox, Ray, Harrison, Allan, Herman, Sandra, Heald, Lisa, Higgs, Christopher, Jendrulek, Isabelle, Johnson, Margaret, Judges, Lucy, Karim, Fatimah, Kinghorn, George, Laurenti, Julie, Lee, Christine, Leen, Clifford, Legg, Ken, Maw, Raymond, Macconachie, Alisdair, Mckernan, Sinead, Mclean, Lorna, Mcmillan, Andrew, Mguni, Sifiso, Morris, Sheila, Mulchay, Fiona, Mullan, Dee, Mullaney, Scott, Murphy, Maurice, Nunn, Andrew, Ong, Edmund, Owen, Maxine, Palfreeman, Adrian, Perry, Nicky, Peters, Barry, Pozniak, Anton, Ronan, Agnes, Skinner, Cecilia, Stroud, Carol, Takawira, Martin, Tamm, Norbert, Thomas, Rachel, Yee, Thynn Thynn, Vanthuyne, An, Wansborough-Jones, Mark, Weber, Jonathan, White, David, Wilkins, Ed, Wiselka, Martin, Williams, Ian, Waugh, Mike, Wotherspoon, Joyce, Youle, Mike, Doyle, Margaret, Goodwin, Edward, Luskin-Hawk, Roberta, Sullivan, James, Verheggen, Rita, Abrams, Donald, Baxter, John, Besch, C. Lynn, Child, Carroll, Cohn, David, Cooper, Pam, El-Sadr, Wafaa, Farrough, Martha, Fisher, Evelyn, Fuentes, Luis, Gordin, Fred, Graeber, Carol, Kelly, Mary Ellen, Kostman, Jay, Lattanzi, Kelly, Macarthur, Rodger, Makohon, Linda, Markowitz, Norman P., Martinez, Norma, Mastro-Polak, Diane, Mitchell, Vinnie, Mushatt, David, Patterson, Kathryn, Perez, George, Rosmarin, Corey, Rouff, Jack R., Saldanha, Jennifer, Sampson, James, Sawyer, Robert, Standridge, Barbara, Sweeton, Bentley, Tedaldi, Ellen, Thompson, Melanie, Valencia, Patricia, Verlinghieri, Gwen, Walker, Janice, Watson, Vicky, Williams, Bruce, Armstrong, Adam, Banks, Susan, Blazes, David, Barile, Anthony, Coelho, Linda, Dennis, Marilyn, Flaks, Hannah, Gilcrest, Joyce, Gittens, Kathleen, Hopper, Shelia, Humphries, M. J., Spooner, Katherine, Tamminga, Cindy L., Vita, Jean, Wegner, Scott A., Wortmann, Glenn, Bisby, Nicole, Blake, William, Brown, Sheldon, Chilliade, Phillippe, Cole, Teresa, Elliot, Katherine, Geisler, Christiane, Goetz, Matthew, Gomez-Perez, Elizabeth, Helman, Jami, Nahass, Ronald, Leflore, Dirk, Marston, Barbara, Obregon, Maria, Petrolati, Jennifer, Pitrak, David L., Roland, Robert, Rosa, Carol, Rossman, Barbara, Schlueter Wirtz, Susan, Schuck, Suzanne, Scretchings, Tiffany, Simon, Gary, Smith, Mack, Summers, Kimberley, Werhane, Mary Jo, Arduino, Roberto, Bell, Brian, Breaux, Katherine, Cuervo, Hilda, Hale, Carl, Lewis, Stanley, Mall, Mark, Mora, Fransisco, Diez, Martine M., Okhuysen, Pablo, Rodriguez-Barradas, Maria, Schrader, Shannon R., Healy, Lynn, Kaszubski, Chris, Kolber, Michael, Tanner, Tom, Armstrong, Joann, Dahlke, Jennifer, Johnson, Leonard, Kaminski, Patricia, Rhame, Frank, Shoden, Cheryl, Temesgen, Zelalem, Urbanich, Marcy, Valenti, Sharon, Zervos, Marcus, Barrick, Bill, Chaitt, Doreen, Hahn, Barbara, Lane, Cliff, Martell, Dennis, Mcnay, Laura, Metcalf, Julia, Powers, April, Tavel, Jorge A., Loveless, Karen, Peterson, Sue, Sweek, Suzanne, Albrecht, Helmut, Antoine, Nicole, Pell, Paula, Gatell, Jose Maria, Hoy, Jenny, Lifson, Alan, Pederson, Court, Borup, Liselotte, Dragsted, Ulrik Bak, Greve, Anne Fau, Jensen, Karoline, Jens Lundgren, Mollerup, David, Pearson, Mary, Phillips, Andrew, Aboulhab, Jamila, Babiker, Abdel, Cordwell, Brooke, Darbyshire, Janet, Hack, Lisa, Hooker, Malcolm, Moraes, Yolanda, Newberry, Douglas, Nuwagaba-Biribonwoha, Harriet, Hooff, Fionna, Denning, Eileen, Holland Klemme, Leslie, Carey, Cate, Chan, Fonnie, Cooper, David, Courtney-Rodgers, David, Drummond, Fraser, Jacoby, Simone, Law, Matthew, Stewart, Morgan, Pett, Sarah, Alloo, Zarina, Bebchuk, Judy, Bollenbeck, Patty, Duchene, Alain G., Fosdick, Lisa, Harrison, Merrie, Krum, Eric, Larson, Gregg, Meger, Sue, Neaton, James, Nelson, Ray, Quan, Siu-Fun L., Schultz, Terri, Telke, Susan, Thackeray, Lisa, Thompson, Greg, Wentworth, Deborah, Wyman, Nicole, Duncan, William, Ferguson, Elaine, Fox, Lawrence, Gettinger, Nikki, Herrera, Janet, Luzar, Mary Anne, Maeshiro, Mieko, Martinez, Ana, Oseekey, Karen, Baigent, Greg, Capra, William, Duliege, Anne-Marie, Fitzgerald, Linda, Kwakkelstein, Marthin, Maral, Jean, O Hara, Mary, Sahner, David, Weber, Claire, Adam-Perchec, Christine, Barron, Nigel, Bell, Mary Louise, Dolan, Sandra, Eckstrand, Julie, Hicks, Steven, Mcauley, George, Beck, Sharon, Brown, Shawn, and Rupert, Adam

38. Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

Author

Yilmaz, Bahtiyar, Ruckstuhl, Lisa, Müllhaupt, Beat, Magenta, Lorenzo, Kuster, Melanie Harrer, Clerc, Olivier, Torgler, Ralph, and Semmo, Nasser

Subjects
610 Medicine & health, 3. Good health
Abstract

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fresh stool sample the week before their study visit, from which microbial DNA was extracted and sequenced for the 16S rRNA region in an Illumina MiSeq2 platform. Microbial and statistical analyses were conducted to determine the alpha-diversity (number of different taxa within a sample) and beta-diversity (number of overlapping taxa between samples). Stool samples from 58 patients were eligible for analysis. There were 27 patients with HCV genotype 1, 10 with genotype 2, 16 with genotype 3, and 5 with genotype 4. No statistically significant differences in gut microbiota diversity, species richness, or microbial community pattern were found at baseline and at post-treatment Week 12. Lack of statistically significant differences remained consistent in further analysis by demographic and baseline disease characteristics. Surprisingly, no statistically significant changes in alpha- and beta-diversity were seen in the microbiota after GLE/PIB treatment, though there was a trend toward less richness over time. Further investigation is needed into this unexpected outcome to better understand the role of HCV treatment and the gut microbiota.

39. Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy

Author

Zuber, Jean-Philippe, Calmy, Alexandra, Evison, John M., Hasse, Barbara, Schiffer, Veronique, Wagels, Thomas, Nuesch, Reto, Magenta, Lorenzo, Ledergerber, Bruno, Jenni, Rolf, Speich, Rudolf, Opravil, Milos, Zuber, Jean-Philippe, Calmy, Alexandra, Evison, John M., Hasse, Barbara, Schiffer, Veronique, Wagels, Thomas, Nuesch, Reto, Magenta, Lorenzo, Ledergerber, Bruno, Jenni, Rolf, Speich, Rudolf, and Opravil, Milos

Abstract

This study aimed to assess the long-term course of pulmonary arterial hypertension related to infection with human immunodeficiency virus (PAHRH) and the influence of antiretroviral therapy (ART) on its characteristics. We retrospectively analyzed all 47 patients in the Swiss HIV Cohort Study in whom PAHRH was diagnosed. Among 35 patients who underwent follow-up Doppler echocardiography, the right ventricular systolic pressure over right atrial pressure gradient increased by a median of 25 mm Hg in 9 patients who had not received ART, decreased by a median of 3 mm Hg in 12 patients who had received nucleoside analogs, and decreased by a median of 21 mm Hg in 14 patients who had received highly active ART (HAART) (P < .005). Among all 47 patients, median duration of survival after PAHRH diagnosis was 2.7 years. HAART significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect of combination ART in patients with PAHRH

40. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.

Author

Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens J, and The Swiss Hepatitis C Cohort Study

Subjects
Drug Therapy, Combination, Female, Hepacivirus isolation & purification, Hepatitis C, Chronic genetics, Humans, Male, Middle Aged, Prospective Studies, Retrospective Studies, Switzerland, Treatment Outcome, Antiviral Agents therapeutic use, Hepacivirus genetics, Hepatitis C, Chronic drug therapy
Abstract

Background: The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete., Aims of the Study: We retrospectively and prospectively evaluated treatment results after the introduction of DAA in Switzerland in a cohort of patients with CHC., Methods: We examined 565 patients who received DAA treatment for CHC between November 2013 and June 2016 with regard to HCV genotype, fibrosis stadium, treatment and outcome. In addition, outcome of re-treatment and resistance-associated substitutions (RAS) in patients that did not achieve sustained virological response (SVR) were evaluated. The majority of patients participate in the Swiss Hepatitis C Cohort Study. Data were evaluated in an intention-to-treat and a modified intention-to-treat analysis., Results: Overall SVR rate for all patients was 94% (530 of 565, 95% CI 92-96%). Of 350 patients with HCV genotype 1 CHC, 335 achieved SVR, resulting in an SVR rate of 96% (335 of 350, 95% CI 94-98%). Patients with HCV genotype 2 achieved SVR in 94% (48 of 51, 95% CI 87-100%). Patients with HCV genotype 3 showed SVR of 92% (98 of 107, 95% CI 87-97%). In patients with HCV genotype 4, the SVR rate was substantially lower at 85% (49 of 57, 95% CI 76-94%). The rate of advanced liver fibrosis (Metavir F3/F4) assessed by means of liver biopsy or Fibroscan® in the entire patient population was 71% (404 of 565). Out of 35 patients that did not achieve SVR after DAA treatment, 32 had a relapse and 3 patients showed viral breakthrough. In 17 of 35 cases (49%) patients were treatment naïve and 21 of 35 patients (60%) were cirrhotic. RAS genotyping of HCV was performed in 14 patients. Nine of these 14 patients (60%) carried mutations in the NS5A region of the virus genome. Twenty-seven percent of patients who experienced treatment failure were not treated with recommended regimens as a result of drug availability and reimbursement limitations., Conclusion: In Switzerland, novel DAA treatments for CHC reflect the positive results from registration trials. Genotypes 2 and 4 remained more difficult to treat between 2014 and 2016. Patients who experienced a relapse after DAA treatment in Switzerland predominantly showed mutations in the NS5A region of the virus genome. DAA treatment limitations in Switzerland did prevent optimal treatment regimens in some patients.

Published
2018
Full Text
View/download PDF

41. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.

Author

De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, and Garcia-Pagan JC

Subjects
Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Europe, Female, Gastrointestinal Hemorrhage chemically induced, Humans, Male, Middle Aged, Splanchnic Circulation physiology, Vitamin K antagonists & inhibitors, Young Adult, Anticoagulants adverse effects, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Liver Cirrhosis complications, Venous Thrombosis drug therapy
Abstract

Background: Direct-acting oral anticoagulants (DOACs) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOACs and to report adverse effects, complications and short-term outcome., Methods: Data collection including demographic information, laboratory values, treatment and complications through the Vascular Liver Disease Interest Group Consortium., Results: Forty-five centres (90%) of the consortium completed the initial eCRF. We report here a series of 94 patients from 17 centres. Thirty-six patients (38%) had cirrhosis. Child-Pugh score was 6 (range 5-8), and MELD score 10.2 (range 6-19). Indications for anticoagulation were splanchnic vein thrombosis (75%), deep vein thrombosis (5%), atrial fibrillation (14%) and others (6%). DOACs used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26.5 months (non-cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding. Treatment with DOACs was stopped in three cases. The major reasons for choosing DOACs were no need for monitoring or inadequacy of INR to guide anticoagulation in cirrhotic patients. Renal and liver function did not change during treatment., Conclusions: A consistent number of patients with SVT and/or cirrhosis are currently treated with DOACs, which seem to be effective and safe. These data provide a basis for performing randomized clinical trials of DOACs vs. low molecular weight heparin or vitamin K antagonists., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2017
Full Text
View/download PDF

42. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.

Author

Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Battegay M, and Bernasconi E

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anti-HIV Agents administration & dosage, Case-Control Studies, Cohort Studies, Female, Humans, Male, Middle Aged, Risk Assessment, Switzerland epidemiology, Young Adult, Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active methods, Apolipoproteins B blood, Coronary Disease epidemiology, HIV Infections drug therapy, Lipoproteins, LDL blood
Abstract

Objectives: HIV infection and exposure to certain antiretroviral drugs is associated with dyslipidemia and increased risk for coronary events. Whether this risk is mediated by highly atherogenic lipoproteins is unclear. We investigated the association of highly atherogenic small dense low-density lipoproteins (LDLs) and apolipoprotein B and coronary events in HIV-infected individuals receiving antiretroviral therapy., Methods: We conducted a case-control study nested into the Swiss HIV Cohort Study to investigate the association of small dense LDL and apolipoprotein B and coronary events in 98 antiretroviral drug-treated patients with a first coronary event (19 fatal and 79 nonfatal coronary events with 53 definite and 15 possible myocardial infarctions, 11 angioplasties or bypasses) and 393 treated controls matched for age, gender, and smoking status. Lipids were measured by ultracentrifugation., Results: In models including cholesterol, triglycerides, high-density lipoprotein cholesterol, blood pressure, central obesity, diabetes, and family history, there was an independent association between small dense LDL and coronary events [odds ratio (OR) for 1 mg/dL increase: 1.06, 95% confidence interval (CI): 1.00 to 1.11] and apolipoprotein B (OR for 10 mg/dL increase: 1.16, 95% CI: 1.02 to 1.32). When adding HIV and antiretroviral therapy-related variables, ORs were 1.04 (95% CI: 0.99 to 1.10) for small dense LDL and 1.13 (95% CI: 0.99 to 1.30) for apolipoprotein B. In both models, blood pressure and HIV viral load was independently associated with the odds for coronary events., Conclusions: HIV-infected patients receiving antiretroviral therapy with elevate small dense LDL and apolipoprotein B are at increased risk for coronary events as are patients without sustained HIV suppression.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results